Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood

NEW YORK, January 9, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On January 6, 2014, Gilead Sciences, Inc. (Gilead) announced the retirement of Kevin Young CBE, Executive Vice President - Commercial Operations, effective February 4, 2014. According to the Company, Mr. Young will continue to work directly with Gilead's management team as a Senior Advisor. John Martin, PhD, Chairman and CEO at Gilead Sciences commented on Mr. Young's retirement, "Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas and ensuring a consistent and clear focus on the needs of patients around the world. I have deeply valued his insights and perspectives, and look forward to a continued partnership as Kevin remains with Gilead in an advisory role." The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

Aegerion Pharmaceuticals, Inc. Research Report

On January 6, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) stock declined 6.76% to end the day's trading session at $68.59 compared to the previous day's closing price of $73.56. The Company's stock went down 3.34% in the past three trading days, compared to the Dow Jones Industrial Average Index which decreased 0.91% over the same trading period. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=    

http://www.analystscorner.com/r/full_research_report/a3f6_AEGR

--

Celldex Therapeutics, Inc. Research Report

On January 6, 2013, Celldex Therapeutics, Inc. (Celldex) stock declined 8.03% to end the day's trading session at $22.33 compared to the previous day's closing price of $24.28. The Company's stock went down 7.77% in the past three trading days, compared to the Dow Jones Industrial Average Index, which decreased 0.91% over the same trading period. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/b443_CLDX

--

Alnylam Pharmaceuticals, Inc. Research Report

On January 6, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it will present an overview of the Company including a review of the company's goals and guidance, at the 32nd Annual J.P. Morgan Healthcare Conference on January 13, 2014, Monday, at 11:30 a.m. PT / 2:30 p.m. ET. According to the Company, the conference will be held at the Westin St. Francis Hotel in San Francisco, California.  Alnylam informed that a live audio webcast of the presentation will be available on the News & Investors section of the Company's website. The Full Research Report on Alnylam Pharmaceuticals, Inc. -  including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

--

Ironwood Pharmaceuticals Inc. Research Report

On January 6, 2014, Ironwood Pharmaceuticals, Inc. (Ironwood) announced that it is scheduled to present a corporate update at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 1:30 p.m. PT / 4:30 p.m. ET at the Westin St. Francis Hotel in San Francisco. The Company informed that it will also host a question and answer session on the same day, beginning at 2:00 p.m. PT / 5:00 p.m. ET. According to the Company, a live webcast of the presentation as well as a replay of the same will be available on Ironwood's website for interested parties. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner